Journal of Urology and Andrology Research (JUAR) is an international, open-access, peer-reviewed journal dedicated to advancing urologic and andrologic care by publishing the highest quality evidence syntheses, clinical research, and methodological studies.
We invite medical residents & fellows, urologists, andrologists, reproductive medicine specialists, systematic reviewers, researchers, and policymakers to submit their work to a journal committed to methodological rigor and clinical relevance. We are dedicated to disseminating innovative research that helps practitioners interpret and apply the best available evidence to improve patient outcomes and healthcare delivery worldwide — with a special focus on the Australasian, Central-Asian, Asia-Pacific, Africa, Middle East regions, and beyong.
We seek submissions that address:
- Prostate cancer screening, diagnosis, and treatment – balancing early detection with overdiagnosis
- Management of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS)
- Male infertility – diagnostic algorithms, surgical sperm retrieval, and assisted reproductive outcomes
- Erectile dysfunction as a cardiovascular risk marker – evidence for integrated care
- Endourology and stone disease – comparative effectiveness of PCNL, RIRS, and ESWL
- Robotic and minimally invasive surgery in urologic oncology
- Hypogonadism and testosterone replacement therapy – benefits, risks, and evidence gaps
- Urinary incontinence and pelvic floor disorders – non-surgical vs. surgical management
- Reconstructive urology – evidence for urethral stricture and hypospadias repair techniques
- Pediatric urology – evidence-based management of congenital anomalies
- Environmental and occupational impacts on male reproductive health
- Health equity and access to urologic and andrologic services globally
- Ethics of reproductive technologies, informed consent, and surgical innovation
- Implementation of evidence-based guidelines in low-resource settings
CURRENT ISSUE
Volume 1, Issue 1, 2026
Historically, dermal grafts were the first autografts used but have fallen out of favor due to high rates of penile shortening (45–70%) and de novo ED (up to 66.7%). Saphenous vein grafts (SVG) demonstrate an initial success rate of ~85.6%, though long-term follow-up indicates a decline in straightness and rising ED rates (22.5%). Tunica albuginea and tunica vaginalis grafts show high technical success (90–100%) with low metabolic demand. More contemporary options, specifically fascia (lata and temporalis) and buccal mucosa grafts (BMG), show superior outcomes. Fascia grafts report technical success rates near 100% with minimal shortening. BMG demonstrates a 94.1% success rate with low de novo ED (0–10%) and rapid tissue integration.
A total of 50 patients who underwent RIRS were included in the study. The patients were aged between 55 and 65 years. Among them, 28 were males and 22 were females. The average stone size was greater than 1.5 cm, with a density ranging from 1000 to 1200 HU.All procedures were performed under general anesthesia. A flexible ureteroscope and holmium laser were used during surgery. The average operative time ranged from 1.5 to 2 hours.The study demonstrated a 100% stone-free rate. The overall postoperative complication rate was 8%. According to the Traxer (PULS) classification, no ureteral injury (Grade 0) was detected in 98% of cases, while minor Grade 1 ureteral injury was observed in 2% of patients.
The results indicate that RIRS is a highly effective and safe method for the treatment of nephrolithiasis.